HDL-cholesterol or apolipoprotein AI: How to choose?;HDL-cholesterol ou apolipoproteine AI: Quel parametre choisir?

Annales de Biologie Clinique

Volumn 54, Issue 10-11, 1996, Pages 349-352

  Bigot Corbel, E ^a   Amory Touz, M C ^b   Mainard, F ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Apolipoprotein AI; HDL cholesterol

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; HUMAN; ARTERIOSCLEROSIS; BLOOD; MAXIMUM ALLOWABLE CONCENTRATION;

APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; HUMANS; MAXIMUM ALLOWABLE CONCENTRATION;

EID: 0030347734     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Conseil d'administration de l'ARCOL (1989) Consensus français sur le cholestérol et les dyslipoprotéinémies. Rev Prat 39, 972-974
2. Farnier M (1991) Le consensus ARCOL, norme française en matière de dyslipidémie. JAMA (Hors série) janvier 6-7
3. Beucler I, Jacotot B (1995) Nouvelles de l'Arcol : cholestérol-HDL , fiche technique ARCOL/SFBC (addendum). Risques 6, 5
4. Marcovina SM, Alberts JJ, Dati F, Ledue TB, Ritchie RF (1991) International Federation of Clinical Chemistry Standardization project for measurement of apolipoproteins A1 and B. Clin Chem 37, 1678-1682
5. Gordon DJ, Probstfield JL, Garrison RJ (1989) High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15
6. Anderson KM, Castelli WP, Levy D (1987) Cholesterol and mortality, 30 years follow-up from the Framingham study. JAMA 257, 2176-2180
7. Puchois P, Kandoussi A, Fievet A, Fourrier JL, Bertrand M, Koren E, Fruchart JC (1987) Apolipoprotein AI containing lipoprotein in coronary artery disease. Atherosclerosis 68, 35-40
8. Marzullo C, Michotey O, Bourderont D, Levy J, Jung S, Tissot J, Huber-Braun C, Dorr R (1994) Étude comparative des lipides, apoprotéines el lipoprotéines dans un groupe de sujets coronariens et dans une population témoin. Ann BiolClin 52, 717-720
9. De Backer G, Rosseneu M, Delsypere JP (1982) Discriminative value of lipids and apoproteins in coronary heart disease. Atherosclerosis 42, 197-203
10. Noma A, Yokosuka T, Kitamura K (1982) Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary heart disease. Atherosclerosis 49, 1-7
11. Ardissone JP, Cohen-Billiemaz A, Heim M, Gulian JM, Giordanella JP, Bory M, Chanel M (1992) Étude comparative des lipoparticules LpAl, du cholestérol HDL et de l'apolipoprotéine AI, dans une population témoin, dans un groupe de sujets coronariens et dans un groupe de sujets à coronaires angiographiquement normales. Ann Biol Clin 50, 149-153
12. Chivot L, Mainard F, Bigot E, Bard JM, Auget JL, Madec Y, Fruchart JC (1990) Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoprotein CIII and E. Atherosclerosis 82, 205-211
13. Mainard F, Auget JL, Vest P, Madec Y (1994) Comparative study of risk factors in patients undergoing coronary or femoropopliteal artery bypass grafting. Br Heart J 72, 542-547
14. Shaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PW F (1994) Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein AI levels in the Framingham Offspring study. J Lipid Res 35, 871-882
15. Mainard F, Ozanne P, Madec Y (1982) Correlation of high-density lipoproteins with apolipoproteins A and B. Selectivity criterion for three precipitation reagents. Clin Chem 28, 729-730
16. Steinmetz J, Tarallo P, Fournier B, Caces E, Henny J, Siest G (1994) Valeurs de référence des apo AI et B avec une méthode étalonnée sur les standards IFCC. Option/Bio 119 (suppl), 3-4